← Search & browse all drugs

tralokinumab

D11AH07

Forms & Strengths

Subcutaneous solution in pre-filled syringe: 150 mg/mL
Subcutaneous solution in pre-filled pen (auto-injector): 150 mg/mL

Adult Dosing

Atopic dermatitis: Initial loading dose of 600 mg (four 150 mg injections) subcutaneously
Atopic dermatitis: Maintenance dose of 300 mg (two 150 mg injections) subcutaneously every 2 weeks
May consider dosing every 4 weeks in patients whose skin is completely clear after 16 weeks of treatment

Pediatric Dosing

Pediatric patients 12 to 17 years: Initial loading dose of 600 mg (four 150 mg injections) subcutaneously
Pediatric patients 12 to 17 years: Maintenance dose of 300 mg (two 150 mg injections) subcutaneously every 2 weeks
Safety and efficacy in pediatric patients below 12 years of age have not been established

Indications

Treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients (12 years and older) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Mechanism of Action

Human monoclonal antibody (IgG4 kappa) that specifically binds to interleukin-13 (IL-13) and neutralizes its signaling
Inhibits the IL-13 pathway, reducing the biological activity of IL-13 which plays a key role in the pathogenesis of atopic dermatitis inflammation

Contraindications

Severe hypersensitivity to tralokinumab or to any of the inactive ingredients

Adverse Reactions

Upper respiratory tract infections (primarily nasopharyngitis)
Injection site reactions (e.g., pain, erythema, swelling)
Conjunctivitis
Keratitis
Eosinophilia

Drug Interactions

Live vaccines: Avoid concurrent administration during treatment with tralokinumab
CYP450 substrates: No clinically significant pharmacokinetic interactions expected with CYP substrates, as tralokinumab is cleared via proteolytic catabolism

Curated Content: Needs Vetting Before Put to Clinical Use